Brought to you by 
Series D brings in $43mm for Avedro
27 Mar 2013
Executive Summary
Ophthalmic device and drug developer Avedro Inc. has raised $43mm through its Series D venture round led by Abingworth. Third Point also made a significant investment, and was joined by existing shareholders Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Venture Partners, Borealis Ventures, and Echelon Ventures. Abingworth and Third Point will gain representation on Avedro’s board. The company will use the proceeds for R&D activities involving corneal crosslinking (for cataract and refractive surgery), to gain US approval for future products, and for global commercialization.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
- Laser
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D brings in $43mm for Avedro
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice